

Financial news for AST dated on 2019-01-24: Asterias Offers Top-Line 12-Month Data Update For OPC1 Phase 1/2a Trial In Severe Spinal Cord Injury

Financial news for AST dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for AST dated on 2018-12-17: Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018

Financial news for AST dated on 2018-11-27: Asterias Biotherapeutics Announces Fourth Patient Dosed In First-In-Human Clinical Study Of Immunotherapy VAC2 In Non-Small Cell Lung Cancer

Financial news for AST dated on 2018-11-11: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for AST dated on 2018-11-09: Asterias Biotherapeutics, Inc. Q3 EPS \$(0.08) Beats \$(0.10) Estimate

Financial news for AST dated on 2018-11-08: BioTime to Acquire Asterias Biotherapeutics for 0.71 Shares of BioTime for Each Share of Asterias Owned, Worth \$1.49/Share

Financial news for AST dated on 2018-10-31: Asterias Biotherapeutics Announces Independent Data Review Panel Recommended Moving Forward With OPC1 Spinal Cord Injury Study; Meeting With FDA Remains On Track For End Of 2018

Financial news for AST dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for AST dated on 2018-10-01: Asterias Biotherapeutics Announces an IP License Agreement with an Affiliate of Novo Nordisk, Asterias to Recieve \$2M Upfront

Financial news for AST dated on 2018-09-20: FDA Accepts Asterias Biotherapeutics' Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program

Financial news for AST dated on 2018-09-12: Asterias Provides 24 Month Cohort 2 Update For OPC1 Phase 1/2a Clinical Trial In Severe Spinal Cord Injury

Financial news for AST dated on 2018-09-04: Asterias Biotherapeutics Announces Safety Review Committee For First Clinical Trial Of VAC2 Has Recommended Continuation Of Study And Move To Open Enrollment In The Advanced Disease Cohort

Financial news for AST dated on 2018-08-10: Raymond James Downgrades Asterias Biotherapeutics, Inc. Common Series A to Market Perform

Financial news for AST dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for AST dated on 2018-08-09: Asterias Biotherapeutics, Inc. Common Series A Q2 EPS \$(0.13) Misses \$(0.10) Estimate

Financial news for AST dated on 2018-07-31: Asterias Provides 12 Month Cohort 3 And 4 Update For AST-OPC1 Phase 1/2a Clinical Trial In Severe Spinal Cord Injury

Financial news for AST dated on 2018-07-17: Benzinga Pro's 5 Stocks To Watch Today

Financial news for AST dated on 2018-07-17: Asterias Provides 6 Mo. Data Readout From Its AST-OPC1 Phase 1/2a Clinical Trial, Says Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury Site and Improved Motor Function

Financial news for AST dated on 2018-07-12: Asterias Biotherapeutics Reports New Exclusive License Deal With The Regents Of The University Of California For Stroke IP; Second Pre-Clinical Collaboration Initiated To Test Efficacy Of AST-OPC1 For The Treatment Of Stroke

Financial news for AST dated on 2018-07-11: Mid-Afternoon Market Update: Dow Down Over 200 Points; Achieve Life Sciences Shares Spike Higher

Financial news for AST dated on 2018-07-11: Mid-Day Market Update: Crude Oil Down Over 2%; Simulations Plus Shares Plunge

Financial news for AST dated on 2018-07-11: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for AST dated on 2018-07-11: Mid-Morning Market Update: Markets Open Lower; Fastenal Profit Tops Views

Financial news for AST dated on 2018-07-11: Asterias Biotherapeutics Shares Up 26% Premarket After Safety Review Committee Recommended Proceeding As Planned With AST-VAC2 Clinical Trials

Financial news for AST dated on 2018-07-11: Asterias Biotherapeutics Announces Favorable Outcome From Trial Of AST-VAC2 For Non-Small Cell Lung Cancer; Safety Review Committee Recommended Co. Continue Trial Without Modification

Financial news for AST dated on 2018-06-30: The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Financial news for AST dated on 2018-06-12: Asterias Biotherapeutics Reports First Patient Dosed In First In Human Clinical Study Of AST-VAC2 In Non-Small Cell Lung Cancer

Financial news for AST dated on 2018-06-05: Asterias Biotherapeutics Shares Up 15.6% Premarket After Independent Data Monitoring Committee Completed Last Intermediate Review Of AST-OPC1 Clinical Trial In Acute Spinal Cord Injury And Recommended Continuation Of Study Without Modification

Financial news for AST dated on 2018-06-05: Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review Of AST-OPC1 Clinical Trial In Acute Spinal Cord Injury

Financial news for AST dated on 2018-05-14: Shares Of Micro-Cap Regenerative Biotech Co. Asterias Biotherapeutics Up 19.0% On High Trading Volume; No Company-Specific News To Justify Price Action

Financial news for AST dated on 2018-05-09: Asterias Biotherapeutics, Inc. Common Series A Q1 EPS \$(0.04) Beats \$(0.13) Estimate, Sales \$500K Beat \$490K Estimate

Financial news for AST dated on 2018-03-15: Asterias Biotherapeutics Reports Q4 EPS \$(0.12) vs \$(0.16) Est.

Financial news for AST dated on 2018-02-25: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for AST dated on 2018-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2018

Financial news for AST dated on 2018-02-22: B. Riley Initiates Coverage On Asterias Biotherapeutics, Inc. Common Series A with Buy Rating, Announces \$6.00 Price Target

Financial news for AST dated on 2018-02-08: 19 Biotech Stocks With Clinical Trial Outcomes In February

Financial news for AST dated on 2018-01-05: 36 Biggest Movers From Yesterday

Financial news for AST dated on 2018-01-04: 33 Stocks Moving In Thursday's Mid-Day Session

Financial news for AST dated on 2017-12-19: Asterias Biotherapeutics Completes Enrollment Of SCiStar Study

Financial news for AST dated on 2017-11-29: Asterias Biotherapeutics, Inc.: Mulroy Michael H. (Director, President and CEO) Buys 2,076 @ Avg Price: \$2.41 (Form4

Financial news for AST dated on 2017-11-14: Asterias Biotherapeutics Reports Q3 EPS \$(0.14) vs. \$(0.14) Est., Sales \$1.688M vs. \$1.48M Est.

Financial news for AST dated on 2017-10-16: Asterias Biotherapeutics Reports \$10.4M Registered Direct Offering

Financial news for AST dated on 2017-10-02: Asterias Biotherapeutics Reports 2 Significant Developments For Spinal Cord Injury Program: '67% of Cohort 2 subjects recovered 2 or more motor levels on at least 1 side through 12 months,' 'AST-OPC1 receives RMAT Designation'

Financial news for AST dated on 2017-09-26: Asterias Gets Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer

Financial news for AST dated on 2017-09-25: Asterias Says its AST-OPC1 Clinical Trial Will Continue as Planned Following Recommendation of Data Monitoring Committee

Financial news for AST dated on 2017-08-30: Asterias Biotherapeutics Reports Preclinical Data On AST-OPC1 For Treatment Of Subacute Cervical Spinal Cord Injury Published In Peer-Reviewed Publication Consistent With Early Data Read-Outs From

Ongoing SCiStar Phase 1/2a Trial

Financial news for AST dated on 2017-07-10: Asterias Biotherapeutics Receives FDA Clearance to Enroll Patients in SCiStar Study

Financial news for AST dated on 2017-06-13: Asterias Biotherapeutics Reports New 9-Month Follow-Up Data From AIS-A 10M Cell Cohort Showed 3 Of 6 Patients Recovered 2 Levels Of Motor Function

Financial news for AST dated on 2017-05-23: Asterias Biotherapeutics Announces CEO Steve Cartt To tTep Down June 25

Financial news for AST dated on 2017-05-11: Asterias Biotherapeutics Reports Q1 EPS \$(0.13) vs \$(0.18) Est., Sales \$1.89M vs \$1.52M Est.

Financial news for AST dated on 2017-03-28: Asterias Biotherapeutics Reports Q4 EPS \$(0.20) vs \$(0.16) Est., Sales \$1.8M vs \$2.6M Est.

Financial news for AST dated on 2016-11-21: BioTime CEO Shares Updates On Spinal Cord Injury And Dry AMD Therapies

Financial news for AST dated on 2016-11-17: Ryan Chavez Appointed CFO of Asterias Biotherapeutics

Financial news for AST dated on 2016-11-14: Asterias Biotherapeutics Reports Q3 \$(0.24) vs \$(0.17) Est, Revenues \$2.1M vs \$1.5M Est

Financial news for AST dated on 2016-11-14: Asterias Biotherapeutics Reports Accelerating Enrollment Of AST-OPC1 SCiStar Phase 1/2a Study

Financial news for AST dated on 2016-09-27: Asterias Biotherapeutics Reports Dosing of First Patient in New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 in an Expanded Cervical Spinal Cord Injury Patient Population

Financial news for AST dated on 2016-09-15: BioTime Reports Affiliate Asterias Biotherapeutics Gave Positive Interim Efficacy Data from Trial in Patients with Complete Cervical Spinal Cord Injuries

Financial news for AST dated on 2016-09-14: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for AST dated on 2016-09-14: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AST dated on 2016-09-14: Asterias Biotherapeutics Reports Cohort of SCiSTAR Trial Patients Reached Targeted 6-12 Mos. Efficacy Endpoint within 3 Mos.

Financial news for AST dated on 2016-09-07: Asterias Biotherapeutics Reports Interim Efficacy Data from SCiStar Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury Patients

Financial news for AST dated on 2016-08-31: Asterias Biotherapeutics Receives Safety Clearance for AST-OPC1 Phase 1/2a for Highest Dose

Financial news for AST dated on 2016-08-16: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AST dated on 2016-08-15: Asterias Biotherapeutics Reports Q2 EPS \$(0.12) vs. Prior Year Quarter \$(0.10), Rev. \$1.53M vs. Prior Year Quarter \$772K

Financial news for AST dated on 2016-07-12: Asterias Biotherapeutics Completes Enrollment and Dosing For AST-OPC1

Financial news for AST dated on 2016-07-01: CEO Cartt Buys 10,000 Shares of Asterias Biotherapeutic @\$2.40/Share -Form 4

Financial news for AST dated on 2016-05-24: Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1; Data Included in Newly Submitted Patent Application for AST-OPC1

Financial news for AST dated on 2016-05-23: Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness

Financial news for AST dated on 2016-05-23: Chardan Capital Initiates Coverage on Asterias Biotherapeutics at Buy, Announces \$5.50 PT

Financial news for AST dated on 2016-05-17: Chairman Bailey Buys 88,235 Shares of Asterias Biotherapeutics @\$3.40/Share -Form 4

Financial news for AST dated on 2016-05-17: Director Lebuhn Buys 15,000 Shares of

Asterias Biotherapeutics @\$3.40/Share -Form 4

Financial news for AST dated on 2016-05-16: Asterias Biotherapeutics Reports Q1 EPS \$(0.27) Vs Est \$(0.14), Sales \$1.594M Vs Est \$870K

Financial news for AST dated on 2016-05-16: Earnings Scheduled For May 16, 2016

Financial news for AST dated on 2016-05-10: Asterias Biotherapeutics Prices Its 5.15 Million Public Offering

Financial news for AST dated on 2016-05-10: Asterias Biotherapeutics Prices Public Offering of 5,147,059 Units @\$3.40/Unit

Financial news for AST dated on 2016-05-10: Asterias Biotherapeutics Delayed for News.

Financial news for AST dated on 2016-05-09: Asterias Biotherapeutics Reports Offering of Stocks, Warrants, Amount Not Disclosed

Financial news for AST dated on 2016-04-25: Rodman & Renshaw Initiates Coverage on Asterias Biotherapeutics at Buy, Announces \$12.00 PT

Financial news for AST dated on 2016-03-29: Asterias Biotherapeutics Reports Q4 EPS \$(0.13) Vs Est \$(0.13), Sales \$0.608M Vs Est \$1.07M

Financial news for AST dated on 2016-03-29: Earnings Scheduled For March 29, 2016

Financial news for AST dated on 2016-02-29: Asterias Biotherapeutics Names Stephen Cartt as Pres, CEO

Financial news for AST dated on 2016-02-24: Asterias Biotherapeutics Reports Successful End-of-Phase 2 Meeting with FDA for AST-VAC1, FDA Indicated General Agreement With Asterias Development Plan

Financial news for AST dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for AST dated on 2015-12-14: The Five Best Biotech Analyst Calls Of 2015

Financial news for AST dated on 2015-11-19: Benzinga's Top Initiations

Financial news for AST dated on 2015-11-19: FBR Capital Initiates Coverage on Asterias Biotherapeutics at Outperform, Announces \$10.00 PT

Financial news for AST dated on 2015-11-09: Asterias Biotherapeutics Reports Q3 EPS \$(0.09) vs. Est. \$(0.11), Rev. \$1.423M vs. Est. \$440K

Financial news for AST dated on 2015-10-20: Asterias Biotherapeutics to Begin Dose Escalation in SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury

Financial news for AST dated on 2015-10-13: Asterias Biotherapeutics Announces Collaboration with Cell Therapy Catapult

Financial news for AST dated on 2015-09-30: Heraeus Medical, BioTime Subsidiary OrthoCyte Announce Exclusive Worldwide Development, Licensing Agreements

Financial news for AST dated on 2015-09-22: Latin American ADRs Getting Slaughtered, Brazilian Real And Crude Continue To Tumble

Financial news for AST dated on 2015-08-31: Morning Market Gainers

Financial news for AST dated on 2015-08-31: Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury

Financial news for AST dated on 2015-08-10: Asterias Biotherapeutics Reports Inline Q2 Loss \$0.10, Sales \$772K Vs Est \$580K

Financial news for AST dated on 2015-06-30: Mid-Day Market Update: Juno Therapeutics Jumps Following Announcement of 10-Year Collaboration With Celgene

Financial news for AST dated on 2015-06-30: Tuesday's Mid-Day Movers: Juno, Fitbit, Kandi Spike; Puerto Rico News Affecting Stocks

Financial news for AST dated on 2015-06-30: Mid-Morning Market Update: Markets Rise; ConAgra Foods Plans To Exit Private Label Business

Financial news for AST dated on 2015-06-30: Morning Market Gainers

Financial news for AST dated on 2015-06-08: Asterias Biotherapeutics Announces First Patient Treated in Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury

Financial news for AST dated on 2015-06-01: Asterias Biotherapeutics Offers New, Long-Term, Follow-Up Data of AST-VAC1 Results Showing Prolonged Replase-Free Survival in Patients with High-Risk AML

Financial news for AST dated on 2015-05-26: Asterias Biotherapeutics Receives \$11.7M in Proceeds from Exercise of Warrants

Financial news for AST dated on 2015-05-18: Asterias Biotherapeutics Shares Move to Low; May be Attributed to Short-Seller Report

Financial news for AST dated on 2015-05-14: Asterias Biotherapeutics Announces Availability of Abstract with Phase 2 Clinical Data on Cancer Vaccine AST-VAC1 in AML

Financial news for AST dated on 2015-05-05: Lake Street Initiates Coverage on Asterias Biotherapeutics at Buy, Announces \$22.00 PT

Financial news for AST dated on 2015-04-21: Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation

Financial news for AST dated on 2015-04-20: BioTime Announces Positive Clinical Results of OncoCyte's PanC-Dx Diagnostic Test

Financial news for AST dated on 2015-03-05: Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury

Financial news for AST dated on 2015-02-27: MLV Initiates Coverage on Asterias Biotherapeutics, at Buy, Announces \$9.00 PT

Financial news for AST dated on 2015-02-11: Asterias Biotherapeutics CEO Lichtinger Buys 128,205 Shares @\$3.90/Share -Form 4

Financial news for AST dated on 2015-02-10: Asterias Biotherapeutics Completes Public Offering, Raised \$5.5M In Proceeds

Financial news for AST dated on 2015-02-05: Shares of Asterias Biotherapeutics Resume Trade

Financial news for AST dated on 2015-02-05: Asterias Biotherapeutics Prices Public Offering of Common Stock

Financial news for AST dated on 2015-02-05: Asterias Biotherapeutics Prices Offering at \$3.90/Share

Financial news for AST dated on 2015-02-04: Asterias Biotherapeutics Announces Public Offering of Common Stock

Financial news for AST dated on 2015-01-26: BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy

Financial news for AST dated on 2014-12-04: Asterias Biotherapeutics Files Mixed Shelf \$75M

Financial news for AST dated on 2014-10-20: Asterias Biotherapeutics Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury